The invention relates to multispecific polypeptides comprising a first protein for the prevention, treatment or detection of a neurological disorder in the central nervous system, a second protein binding specifically to a protein expressed on the blood brain barrier, wherein the protein expressed on the brain blood barrier mediates enhanced uptake of compounds over the BBB, and a third protein binding specifically to a protein in the CNS.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present invention relates to the field of microbial self-assembling protein fibrils as novel bionanomaterials. More specifically, the present invention relates to protein nanofibril materials comprising Bacillus endospore appendage (ENA) proteins, which are spontaneously folding helix hairpin subunits assembling into alpha-helical multimeric (A-ENA) fibrils with a hydrophobic core and covalently connected by one or more isopeptidic bonds, providing for a nanofibril of high stability and tensile strength. The invention further relates to said protein nanofibrils which are engineered or modified to provide for functionalized bionanomaterials. In particular, the invention relates to methods for recombinant production of said self-assembling protein nanofibrils, and their use in modifying bacterial endospores and endospore activity or pathogenicity.
The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses means and methods for single molecule protein sequencing and/or amino add identification using cleavage inducing agent. Said cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics of said reaction.
The invention relates to the field of CAR-T cell immunotherapy, more specifically the invention relates to production and uses of glyco-engineered CAR-T cells for the improvement of immunotherapy compositions for treatment of cancer, more specifically of solid tumors. The invention specifically relates to human CAR-T cells with a mutated MGAT5 gene, as to provide for surface glycan structures devoid of tetra-antennary N-glycans, which results in a sustained memory when applied in immunotherapy, to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse. The invention further relates to methods for manufacturing of those CAR-T cells, wherein addition of low amounts of DMSO during activation and expansion ex vivo skews T cell populations to a more predominant memory phenotype, thereby providing for improved glycol-engineered CAR-T cell compositions for adoptive T cell transfer.
The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
Provided is a method of characterising a polynucleotide using a transmembrane pore, wherein the pore is a double pore comprising a first Csg G pore, or a homologue thereof, and second CsgG pore, or a homologue thereof.
The present invention provides co-crystals of the anaplastic lymphoma kinase (ALK) and its ligand ALKAL2 and the related leukocyte tyrosine kinase (LTK) and its ligand ALKAL1. The invention also provides computer-assisted and other methods for selecting molecules able to modulate the interaction between ALK, LTK and their respective ligands.
Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP-carboxyterminal fragments.
The present invention relates to the field of tissue regeneration, particularly the field of skin lesions such as wounds, more particularly chronic wounds. The invention provides wound healing compositions. Specifically, the invention provides molecules targeting the Slc7a11 transporter such as antibodies, shRNA, siRNA, locked nucleic acids, peptide nucleic acids and morpholinos for use to treat chronic wounds such as for example diabetic wounds.
The invention relates to the field of predicting (clinical) response of a cancer patient to a therapy comprising an immune checkpoint blocker or to therapy with an immune checkpoint blocker. In particular enriched pre-therapy levels of intra-tumoral CD8 Temra cells and/or intra-tumoral CXCL10-positive macrophages are markers indicative of a positive response. An alternative pre-therapy marker indicative of a positive response relies on detecting enhanced levels of T cell receptor sharing between intra-tumoral and peripheral CD8 Temra cells. The invention therefore refers to methods of e.g. selecting a patient eligible for therapy comprising an immune checkpoint blocker or for therapy with an immune checkpoint blocker including determining the levels of these markers.
The present invention belongs to the field of immunology and relates to proteins and polypeptides comprising an immunoglobulin single variable domain (ISVD) fused with a cytokine. In particular, the present invention provides a chimeric protein which comprises an immunoglobulin single variable domain (ISVD) fused with a cytokine, wherein an internal fusion site of the ISVD is linked to the cytokine, wherein the internal fusion site is located in a loop or turn between two secondary structure elements. The fusion of the cytokine to the ISVD upon binding to the cytokine receptor or receptor subunit(s) allows for the modulation of the cytokine receptor activity and/or downstream signaling.
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 217/04 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
14.
BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 241/50 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to the field of antibody-drug-conjugates (ADCs) and the application of glyco-engineering strategies in a novel site-specific conjugation technology. The invention particularly relates to ADCs wherein a drug entity is conjugated an aminooxy-functionalized linker at di- or trisaccharide N-glycans in the hinge region, and methods for producing the same. More particularly, said conjugate is obtained through oxidized galactose- or sialyl-groups obtained from glyco-engineered eukaryotic cells which produce antibodies with an N-glycan structure that is limited to a shortened Asn- GlcNac-Gal(-Sia) branch in the hinge region of the antibody.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations and substances; Medical preparations and substances; Veterinary preparations; Biological preparations for pharmaceutical, medical and veterinary use; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes; Preparations and substances for use in drug discovery. Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, immune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; drug design; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(Based on 44(d) Priority Application) Pharmaceutical preparations and substances, namely, pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Pharmaceutical preparations and substances, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; (Based on Intent To Use) ; Medical preparations and substances, namely, fungal preparations in the nature of fungal medications for medical purposes, probiotic preparations for medical use, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies,(auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Veterinary preparations in the nature of veterinary pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Biologicals preparations for pharmaceutical, medical and veterinary use, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes, namely, diagnostic preparations for veterinary and medical use, pharmaceutical preparations and biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Preparations and substances for use in drug discovery, namely, preparations for growing cells or for producing biologicals for medical, pharmaceutical, and veterinary purposes, and reagents and media for medical, pharmaceutical and veterinary diagnostic purposes, namely, media and reagents serving as inoculate, clinical medical reagents, and diagnostic reagents Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; Manufacturing of biological preparations; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, immune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; Drug design; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research
INSTITUUT VOOR LANDBOUW- EN VISSERIJONDERZOEK (ILVO) (Belgium)
Inventor
Goormachtig, Sofie
Vlaminck, Lena
Willems, Anne
Pannecoucque, Joke
Abstract
The present invention relates to the field of sustainable agriculture. In particular, the present invention relates to isolated Bradyrhizobium bacteria having enhanced characteristics, including but not limited to enhanced adaptation to the low and medium root zone temperature for example in North-West Europe.
The present invention relates to the field of microbial growth, more specifically microbial overgrowth, even more specifically overgrowth of Enterobacteriaceae, specifically under conditions of apoptosis in the gut such as IBD, colitis, chemotherapy and food borne bacterial infections. The present invention provides inhibitors of a bacterial target, pyruvate formate lyase, which can be used to regulate the overgrowth of Enterobacteriacea.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
C07D 215/02 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.
The disclosure relates to the compounds selectively inhibiting Solute Carrier Family 4 member 4/ Electrogenic Sodium Bicarbonate Cotransporter 1 (SLC4A4/NBCe1). More in particular, said compounds are SLC4A4/NBCe1-inhibiting single domain antibodies, compounds comprising at least one CDR polypeptide of a SLC4A4/NBCe1-inhibiting single domain antibody, and compounds comprising a SLC4A4/NBCe1-inhibiting single domain antibody. Applications of compounds inhibiting SLC4A4/NBCe1 are likewise included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
26.
COMBINATIONS OF SHORT GENETIC VARIANTS IN THE DIAGNOSIS OF ALZHEIMER DISEASE
The invention relates to combinations of Alzheimer disease risk loci, more in particular short genetic variant loci (SGVs). Combinations of such SGVs were identified that are significantly and synergistically pathogenic. Applications of these combinations, such as diagnostic applications, are included as well.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
INSTITUUT VOOR LANDBOUW-EN VISSERIJONDERZOEK (ILVO) (Belgium)
Inventor
Van Hautegem, Tom
Nelissen, Hilde
Inzé, Dirk
Claeys, Hannes Bart
Van Ex, Frédéric
Nuccio, Michael Lee
Ruttink, Tom
Abstract
The disclosure relates to maize plants with altered characteristics including tolerance to abiotic stress such as drought and/or increased water use efficiency, along with methods of using and making the same.
The invention relates to methods of breast tumor analysis relying on the detection of expression levels of specific genes. Such methods find application in, amongst other, predicting the response of a breast cancer patient to immunotherapy or to immunogenic therapy, and in following up such responses. The expression levels of the genes can thus be used in determining which breast cancer patients are most likely to respond to immunotherapy or immunogenic therapy. The genes serving as biomarkers are individually highly performant in predicting the response of a breast tumor to immunotherapy or to immunogenic therapy, but are weak in predicting the response of melanoma to immunotherapy or to immunogenic therapy. Diagnostic kits are likewise part of the invention.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to antibodies or antibody fragments binding to the human and non-humane primate transferrin receptor. The antibodies herein described can be used as agents to deliver pharmaceutical compounds in or across cells in the process of receptor mediated endocytosis and/or transcytosis. As the transferrin receptor is also present at the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase the delivery of pharmaceutical compounds to the central nervous system.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61P 25/00 - Drugs for disorders of the nervous system
31.
Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation
The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and/or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVD, and of targets bound to said protein binding agents. The CI-M6PR binders disclosed herein are thus linked or fused to a further protein binding agent, in particular another antigen-binding protein, such as an ISVD or antibody, relevant for use in therapy, more specifically for treatment of diseases affected by said target antigen bound by said antigen-binding protein. More specifically disclosed herein are CI-M6PR ISVD fusions to antigen-binding proteins specifically binding EGFR, for treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to the field of plant molecular biology, more particularly to the field of agriculture, even more particularly to the field of improving the yield of plants. The present invention provides chimeric genes and constructs which can be used to enhance the yield in plants and crops.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Verstrepen, Kevin
Ho, Ping-Wei
Jarosz, Dan
Abstract
The present invention relates to the field of yeast fermentations. More particularly, the invention relates to mutant alleles useful to engineer industrially relevant traits in yeast.
The present invention relates to the field of glycoproteomics for identifying novel cell surface O-linked glycopeptide epitopes. The invention relates to methods for identifying O-linked glycopeptides, more specifically Tn- or SiaTn-antigen O-glycosylation sites on cell surface proteins, said method comprising a combined workflow of enzymatic treatments of cells or tissue samples to allow specific enrichment and labelling of Tn antigens, followed by mapping of the O-glycopeptides through LC-MS/MS. More specifically, the invention relates to a chemo-enzymatic method to produce labelled O-glycan-peptides from a plasmamembrane-protein extract sample, wherein Sialyltransferase (ST3Gal1/ST3Gal3) treatment is used to protect free galactose against a follow-on treatment with Galactose oxidase, wherein the oxidized glycans are simultaneously labelled. The invention further relates to a tandem mass spectrometry method using an enriched TMT-labelled (Sia)Tn-antigen glycopeptides in a dual fragmentation triggered approach to resolve the identity, localisation and quantification of the O-linked glycan peptides.
The present invention relates to the field of agriculture, even more particularly to the field of increasing the root length and root biomass of plants including also hairy root biomass. The present invention provides chimeric genes and constructs which can be used to increase the root size of crops, to increase the yield of crops and to increase the biomass of hairy roots.
The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions, such as wounds. The invention provides topical plasters and wound healing compositions. Specifically, the invention provides hydrogels compositions of glycyrrhizinic acid analogues. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.
Capnocytophaga canimorsusCapnocytophaga canimorsusCapnocytophaga canimorsus GH29 enzyme. The invention further specifies methods and uses of said enzymes and compositions for production of defucosylated Fc-containing proteins and their therapeutic utility.
The present invention relates to the field of plant genetic engineering, particularly the modulation of gene expression in plant cells for improved regeneration competence. The invention discloses means and methods wherein the Ethylene Response Factor (ERF) and Phytochrome A Signal Transduction 1 (PAT1) transcription factor complex activity in plant cells grants increased regeneration.
The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.
The disclosure relates to a novel method for selection and identification of specific polypeptide binding agents for a target of interest. More specifically, the selection method involves capturing the target of interest on a surface using a first binding agent to form an immobilized antigen complex, selecting for specific antigen-binding polypeptides present in a sample, preferably as a display library, and eluting the target protein and the selective polypeptide binder, using a second binding agent competing for the target binding site of the first binding agent. More specifically, the selection method presented herein provides for an efficient and highly selective medium- to high-throughput technology applicable to recombinant antibody libraries, including immune and unbiased or proteome-wide display libraries, wherein selections can be performed without a need for purified target protein, in physiological conditions.
The invention relates to identification of regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as siRNA molecules. The synaptogyrin-3 inhibitors disclosed herein are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.
PhascolarctobacteriumVeillonellaEubacteriumAgathobacterLactiplantibacillusAnaerostipesAnaerostipes. Aspects and embodiments described herein may be used in the treatment of joint inflammation, symptoms thereof, and underlying diseases and conditions.
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The invention relates to field of neurodegeneration, more particularly to Tau neurotoxicity. The application identifies genes whose reduced expression suppresses pathological Tau mediated effects. These Tau suppressors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and cynomolgus CD8b protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
45.
MAINTAINING REGULATORY T CELL (Treg) FUNCTIONALITY UNDER CONDITIONS TRIGGERING Treg DYSFUNCTIONALITY
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (Germany)
Inventor
Kleinewietfeld, Markus
Hamad, Ibrahim
Côrte-Real, Beatriz
Mueller, Dominik N.
Abstract
The invention relates to protecting regulatory T cells (Tregs) against dysfunctionality as caused in e.g. the auto-immune disease setting. In particular, such protection is warranted in case of adoptive transfer or Tregs as a means of treatment of auto-immune and other diseases, and as a means of controlling transplant or graft rejection. Furthermore in particular, the protection is enabled by inhibiting the Treg mitochondrial sodium/lithium/calcium exchanger.
The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and murine CD163 protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer. The invention further relates to conjugates, in particular conjugates of polypeptides comprising an immunoglobulin domain binding to human and murine CD163 protein and a further moiety, such as a therapeutic moiety, and to applications of such conjugates.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides novel agrochemicals and formulations thereof and the use of these agrochemical formulations for providing abiotic stress tolerance, such as cold and frost tolerance, in plants.
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 47/30 - Derivatives containing the group N—CO—N—aryl or N—CS—N—aryl
A01N 43/707 - 1,2,3- or 1,2,4-TriazinesHydrogenated 1,2,3- or 1,2,4-triazines
Compositions and binding agents specifically binding the Spike protein of Corona viruses via at least two different binding sites and potently neutralizing coronaviruses, in particular sarbecoviruses, such as SARS-COV-1 and SARS-COV-2. The compositions or agents specifically bind to epitopes of the Receptor binding domain (RBD) of the Spike protein wherein both epitopes are conserved over multiple clades of the sarbecoviruses, providing broadly neutralizing pan-specific antibody-based compositions, thereby reducing viral escape. Application and uses of these agents and compositions are disclosed.
Disclosed herein are yeast strains and derivatives thereof. as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast strains and compositions. In particular, the yeast strains produce lower glycerol and higher ethanol, and have a higher temperature tolerance and higher fermentation rate than strains and products currently used in ethanol production processes.
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) (Spain)
Inventor
Rousseau, Frederic
Schymkowitz, Joost
Orlando, Gabriele
Serrano Pubul, Luis
Abstract
The present methods and systems generally relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides an artificial intelligence algorithm which can predict the stability of proteins and protein complexes.
The invention relates to the field of sustainable agriculture, more particularly to means and methods to protect crops against cold and chilling stress. The application provides three novel Flavobacterium strains that upon administration to plants, protect the plants against growth retardation induced by low temperatures.
The present invention relates to the field of structural biology. More specifically, the present invention relates to novel antigen-binding chimeric proteins, their uses and methods in three-dimensional structural analysis of macromolecules, such as X-ray crystallography and high-resolution Cryo-EM, and their use as a therapeutic, diagnostic, or imaging tool. Even more specifically, the invention relates to a fusion of a scaffold protein and an antigen-binding domain wherein the scaffold protein of said fusion interrupts the Immunoglobulin domain topology to form a rigid chimer.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using diffraction of the radiation by the materials, e.g. for investigating crystal structureInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materialsInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present invention is generally related to a method and system for droplet manipulation and more specifically to a method and system for droplet manipulation using electrowetting technology. The methods and systems herein described are of particular interest for analyzing cell to cell interactions, more particularly for screening for immune cell-mediated cell lysis of tumor cells.
The present invention relates to the field of microbiology, in particular to the field of bacterial antibiotic resistance. more particularly to the field of resistance to beta-lactam inhibitors. The invention provides non-natural compounds which induce the aggregation of beta-lactamases, particularly beta-lactamases of class A. In addition, the invention provides combination therapies and pharmaceutical compositions between the non-natural molecules and beta-lactam antibiotics.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
The present invention provides vaccines and compositions, methods and uses of immunogenic vaccine compositions for eliciting an immune response to members of trypanosomatids such as Trypanosoma brucei, T. cruzi and Leishmania species.
The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
The invention relates to the application of inhibition of SLC4A4 (Solute Carrier Family 4 member 4) in the treatment of cancer. This either as monotherapy (such as for treating cancer refractive or poorly responding to immunotherapy) or as combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of SLC4A4 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy.
This disclosure relates to methods of determining the loss of heterozygosity (LOH) status of a tumor and to methods of determining the homologous recombination repair deficiency (HRD) status of a tumor. Such methods further translate into ways of predicting the response of a subject having cancer to treatments or therapies comprising DNA damaging agents and/or agents inhibiting or impairing DNA repair; and into use of such treatments or therapies when the LOH or HRD status of the subject having cancer is positive.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.
The invention relates to antigen-binding protein agents specifically binding the hemagglutinin- neuraminidase (HN) protein of human parainfluenza virus 3 (hPIV-3), with cross-reactivity for Sendai Virus (SeV) as well as human parainfluenza virus serotype 1 (hPIV-1) HN, resulting in a cross-neutralizing binding protein to act as a protection agent against parainfluenza infection and/or disease caused by such an infection. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of broadly blocking HN neuraminidase activity, thereby providing for a novel hPIV-1/-3 cross-neutralizing antiviral protein binding agent. The invention further relates to the use of said antigen-binding proteins in prevention or treatment of acute respiratory tract infections, croup, pneumonia, and exacerbations of chronic obstructive pulmonary disease.
The invention relates to the field of genetic engineering and synthetic biology, more particularly to means and methods for facilitating genetic recombination. The application discloses novel Cre recombinase dependent recombination sites that supports a simultaneous cloning and testing approach.
Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventor
Steyaert, Jan
Pardon, Els
Rasmussen, Soren G.F.
Fung, Juan Jose
Kobilka, Brian
Laeremans, Toon
Abstract
The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using diffraction of the radiation by the materials, e.g. for investigating crystal structureInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materialsInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
VIB VZW (Belgium)
KATHOLIEKE UNIVERSITEIT LEUVEN (Belgium)
Inventor
Morava-Kozicz, Eva
Kozicz, Tamas
Radenkovic, Silvia
Ghesquière, Bart
Abstract
This document relates to methods and materials for treating congenital disorders of glycosylation (CDG; e.g., a phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG)). For example, this document provides methods and materials for using (a) one or more aldose reductase (AR) inhibitors (e.g., epalrestat) and (b) one or more nucleosides to treat a mammal having one or more CDG (e.g., PMM2-CDG).
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
The present invention relates to the field of time-resolved protein sampling, more specifically for use in structural biology, even more specifically for structural analysis of proteins by Cryogenic-electron microscopy (Cryo-EM). The invention provides for methods and devices for preparing vitrified samples for transmission electron microscopy at millisecond time-resolution using a microfluidics-based integrated device. More specifically, the sampling means and methods combine fast mixing with a tunable droplet-on-demand generation to control droplet formation, spraying and sampling velocity, resulting in a sampling method requiring very limited protein amounts.
The present invention provides novel chimeric genes for the production of quillaic acid and derivatives thereof in eukaryotic cells such as yeasts and plants.
The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with a non-human primate CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The application concerns a novel hominid-specific pathway to modulate neuronal excitability. In a first aspect, the application relates to a modulator of the interaction between a LRRC37B protein and the NAV1.6 voltage-gated sodium channel for use as a medicine. Furthermore, means and methods are provided to treat neurological disorders characterized by affected neuron excitability. In further aspects, the invention relates to methods for identification of or for screening for modulators of neuronal excitability.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with murine CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is a non-blocking binder of hCCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general tumour
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to the field of glycoprotein production means and methods. More specifically, the present invention provides for a novel yeast strain with a mutant Och1 gene resulting in modified N-glycosylation properties of said strain. Even more specifically, said mutant Och1 gene comprises a sequence coding for a mutant OCH1 protein in which one amino acid near the catalytic site, corresponding to position 151 of the OCH1 protein of the methylotrophic wild type Pichia pastorisstrain, is deleted. More specifically, the use of said mutant yeast strain for recombinant expression of glycoproteins results in more homogenous mammalian-like N-glycan structures on said heterologously produced glycoproteins.
The invention relates to the application of inhibition of transcription factor 4 (TCF4/ITF2) in the treatment of cancer. This in particular in combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of TCF4/ITF2 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy. Expression levels of TCF4/ITF2 as well as levels of mesenchymal-like cancer cells in a cancer lesion are predictive of future response to immunotherapy early after initiation of the immunotherapy. Further part of the invention are methods of detecting mesenchymal-like cancer cells.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The invention relates to the field of human genetics, more specifically to treatments for a disease or condition associated with an abnormal processing of the Amyloid Precursor Protein (APP), preferably familiar Alzheimer disease (FAD). The invention in particular relates to antisense oligonucleotides (AONs) that can be used for treating such diseases or conditions.
The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides binding molecules, particularly antibodies which bind to the IL-12RP2. The antibodies are able to bring about the killing of cells expressing IL-12R02 on their surface. The invention further relates to pharmaceutical compositions comprising the binding molecules. The binding molecules and pharmaceutical compositions of the invention may be used in therapy and diagnosis. They may be employed to deplete cells expressing IL-12Rp2. As IL-12R[32 is expressed narrowly, predominately on 'type 1 immune cells' such as CD4+ Thl, CD8+ Tel, and 1LC1 cells in autoimmune and inflammatory conditions, the binding molecules of the invention may be used to treat and prevent such conditions via such cell depletion.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides binding molecules, particularly antibodies which bind to the IL-12Rβ2 and gp 130 subunits of the IL-35 receptor (IL-35R). The binding molecules are preferably able to act as agonists of the IL-35R. The invention further relates to pharmaceutical compositions comprising the binding molecules. The binding molecules and pharmaceutical compositions of the invention may be used in therapy and diagnosis. They may be employed to treat or prevent autoimmune and inflammatory conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention relates to the field of affinity purification and provides for means and methods applying protein binding agents competing for a target protein for use as capture and elution tool, wherein the elution agent comprises an immunoglobulin single variable domain (ISVD), and is capable of displacing the capturing binding agent. More specifically, the displacement efficiency of the ISVD-containing protein binding agent is driven by its dissociation kinetics, with a rate constant of dissociation (koff) equal or lower as compared to the capturing agent. Furthermore, said protein binding agents are deployable in high-throughput purification from complex mixtures, or for capturing protein-complexes, thereby facilitating structural, biochemical and physicochemical analysis of said target proteins.
The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.
The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
82.
AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER
The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to binding agents specifically binding to the folate transport complex. More specifically, antibodies or antibody fragments including immunoglobulin single variable domain (ISVD) antibodies are disclosed that bind the human folate receptor alpha (hFOLRα) present at the choroid plexus epithelial cells. The invention further relates to the antibodies and the methods herein described for use to increase the delivery of pharmaceutical compounds to the central nervous system via the process of receptor mediated endocytosis and/or transcytosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A01K 67/027 - New or modified breeds of vertebrates
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The current invention relates to an improved microfluidic device for protein/protein complex purification, as well as an associated methodology and system. In particular it relates to systems and methods for electron microscopy, preferably cryogenic electron microscopy (cryo-EM), on protein samples, comprising: a. at least one microfluidic chip with inlet and outlet and purification device; b. at least one illumination means and detection means for, preferably fluorescence, measurements on the microfluidic chip; c. a pumping system adapted for operable connection to the microfluidic chip, and configured for controlling flow in the operably connected microfluidic chip; d. a microscopy grid, preferably a cryogenic electron microscopy (cryo-EM) grid, for holding fluid samples; e. preferably a cryogenic container, for a cryogenic coolant; f. preferably a transport system for moving the cryo-EM grid between a position for receiving a fluid sample from the microfluidic chip and the cryogenic container; g. a control system, preferably a processor, which receives information on the measurements from the detection means, configured for controlling the pumping system at least based on said information, and further configured for controlling the illumination and detection means and preferably also for controlling the transport system.
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
C07D 239/82 - Oxygen atoms with an aryl radical attached in position 4
SarbecovirusSarbecovirusSarbecovirusSarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. The invention also relates to methods using these binding agents and uses thereof.
This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV-1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. The invention also relates to methods using these binding agents and uses thereof.
The disclosure relates to the field of the human gut microbiome, more particularly, to its effect on health and disease. Provided herein are means and methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.
The invention is situated in the field of cancer treatment. In particular it relates to treatments comprising combining an inhibitor of the pyrimidinergic receptor P2Y6 and an immune checkpoint inhibitor. Further in particular, the treatment is of benefit for cancers poorly responding to immune checkpoint inhibitor therapy.
The present invention relates to a method and composition for prevention and treatment of infections in a subject, in particular with intracellular bacteria. The invention provides an optimized intracellular delivery of an active agent, in particular a nucleic acid, using a nanoparticle formulation including an iNKT cell agonist.
The invention relates to binding agents for targeted protein degradation comprising an Alphabody protein molecule specifically targeting an intracellular protein, and a degrader molecule acting as scavenger of proteasomal activity. Said Alphabody protein-based degrader binding agent forms a ternary complex with the target protein and the E3 ligase in the cell, resulting in activation of targeted protein degradation. Particularly, the binding agent thus comprises cell-penetrating Alphabody proteins linked to a degrader moiety. More particularly, the invention relates to binding agents which are hybrid molecules wherein the degrader moiety is conjugated to the Alphabody protein. More particularly, the invention relates to binding agents comprising degrader moieties specifically binding an E3 ligase complex to enhance ubiquitination and proteasomal degradation of the target specifically binding the Alphabody protein. Most particularly, the invention relates to binding agents comprising MCL1- and MDM4/MDM2-targeting Alphabody-based degrader molecules for use in treatment of diseases associated with said target molecules, preferably for use in treatment of cancer.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
95.
AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER
The present invention relates to a combination comprising an oncolytic virus and an LTBR agonist. The LTBR agonist may be administered separately or may be encoded by the oncolytic virus. Such a combination is particularly useful for use in the treatment of a cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.
The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.
The present invention relates, in part, to vaccine compositions, adjuvants, chimeric proteins, or chimeric protein complexes and their use as vaccines or therapeutic agents. The present invention further relates to methods of vaccination or treatment of various diseases.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Aspects of the invention concern non-naturally occurring molecules capable of downregulating the amount or biological activity specifically of mutant or variant forms of a protein, as well applications thereof.
